Published • loading... • Updated
US FDA Approves AbbVie’s Drug for Parkinson’s Disease
The once-daily pill was backed by late-stage trials showing symptom improvement, while analysts expect a gradual launch as Medicare coverage negotiations continue.
Summary by WTVB
8 Articles
8 Articles
FDA Approves AbbVie’s Once-Daily Parkinson’s Drug Tavapadon - THE DESTINATION
WASHINGTON: (News Desk) – The US Food and Drug Administration has approved AbbVie’s tavapadon treatment for adults with Parkinson’s disease, according to information posted on the regulator’s website Friday. The drug, which will be marketed under the brand name Juvmo, is designed to be taken as a once-daily pill. AbbVie gained access to tavapadon through […] The post FDA Approves AbbVie’s Once-Daily Parkinson’s Drug Tavapadon appeared first on T…
FDA approves AbbVie next-gen dopamine therapy for Parkinson's
The FDA approved AbbVie’s next-generation therapy for Parkinson’s disease, tavapadon, a dopamine agonist that's expected to provide the symptom relief of its predecessors but with fewer side effects. Tavapadon will be branded as Juvmo and ...
Coverage Details
Total News Sources8
Leaning Left1Leaning Right2Center2Last UpdatedBias Distribution40% Center, 40% Right
Bias Distribution
- 40% of the sources are Center, 40% of the sources lean Right
40% Right
L 20%
C 40%
R 40%
Factuality
To view factuality data please Upgrade to Premium
